FDA Approves Kisqali (ribociclib) for HR+/HER2- Metastatic Breast Cancer

Basel, March 13, 2017 - The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news